UBS Initiates Coverage On Chemed with Buy Rating, Announces Price Target of $650
UBS analyst A.J. Rice initiates coverage on Chemed (NYSE:CHE) with a Buy rating and announces Price Target of $650.
Stocks · News reference
The Capitol Forum Posts On X "Chemed: Vitas Healthcare Misdiagnosed Dementia Patients and 'Fudged' Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed Internal Documents Says They Warrant Federal Investigation"
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Chemed’s Subsidiary Roto-Rooter Services Acquires Independent Roto-Rooter Franchise For $60.6M
Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE:CHE) announced it has acquired the largest independent Roto-Rooter franchise, serving a population of approximately
Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.